At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jun 14, 2026 at 18:05 ET
Zymeworks presented Phase 1 dose-escalation data for ZW191, an FRα-targeting ADC, at ESMO Gynaecological Cancers Congress 2026. The drug showed a confirmed objective response rate (cORR) of 78.6% in FRα-positive platinum-resistant ovarian cancer (PROC) patients and 47.4% in FRα-negative patients, with median progression-free survival of 7.6 months. While early-stage, the data suggests ZW191 could address limitations of current FRα-targeted therapies and broaden the treatable population, representing a positive clinical catalyst for the stock.
- ZW191 demonstrated a cORR of 78.6% in FRα-positive (≥75% at PS2+) PROC patients across all dose levels.
- ZW191 demonstrated a cORR of 47.4% in FRα-negative (<75% at PS2+) PROC patients across all dose levels.
- Overall cORR in PROC was 58.8% across all dose levels and 65.2% in the 6.4-9.6 mg/kg dose range.
- Median progression-free survival was 7.6 months across ovarian and endometrial cancer cohorts; median duration of response was not reached.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access